The Claim

The loss of lean body mass associated with glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors is not significantly modified by sex, disease status (obesity, type 1 or type 2 diabetes, or polycystic ovary syndrome), or measurement technique.

Source: The Effects of Glucagon‐Like Peptide‐1 Receptor Agonists and Sodium‐Glucose Co‐Transporter‐2 Inhibitors on Lean Body Mass in Humans: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
53score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Description
1 study reviewed
In plain English

The reduction in lean body mass caused by glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors is the same across men and women, regardless of whether a person has obesity, type 1 diabetes, type 2 diabetes, or polycystic ovary syndrome, and regardless of how the mass is measured.

See the scientific wording

The loss of lean body mass associated with glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors is not significantly modified by sex, disease status (obesity, type 1 or type 2 diabetes, or polycystic ovary syndrome), or measurement technique, indicating that the effect is consistent across diverse clinical populations.

Why this might work

These drugs cause the body to lose calories either by making the person eat less or by flushing sugar out in the urine. To make up for the missing energy, the body breaks down muscle tissue to get amino acids, which are turned into glucose to keep blood sugar stable. This process happens the same way whether the person is male or female, has diabetes or not, or how their muscle mass is measured.

Verified mechanismbased on 1 study

What the research says

1 study
  1. Study: The Effects of Glucagon‐Like Peptide‐1 Receptor Agonists and Sodium‐Glucose Co‐Transporter‐2 Inhibitors on Lean Body Mass in Humans: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials

    This study looked at many people using these weight-loss drugs and found that whether you're male or female, have diabetes or not, or even if they measured your muscle with different machines, you still lost about the same amount of muscle — so the effect is pretty much the same for everyone.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.